CHEWABLE TABLETS AND SUSPENSION
MINTEZOL (Thiabendazole) is an anthelmintic provided as 500 mg chewable tablets, and as a suspension, containing 500 mg thiabendazole per 5 mL. The suspension also contains sorbic acid 0.1% added as a preservative.
MINTEZOL is indicated for the treatment of:
Cutaneous larva migrans (creeping eruption)
Visceral larva migrans
Trichinosis: Relief of symptoms and fever and a reduction of eosinophilia have followed the use of MINTEZOL during the invasion stage of the disease.
Thiabendazole is usually inappropriate as first line therapy for enterobiasis (pinworm). However, when enterobiasis occurs with any of the conditions listed above, additional therapy is not required for most patients.
MINTEZOL should be used only in the following infestations when more specific therapy is not available or cannot be used or when further therapy with a second agent is desirable: Uncinariasis (hookworm:
Ancylostoma duodenale); Trichuriasis (whipworm); Ascariasis (large roundworm).
Published Studies Related to Mintezol (Thiabendazole)
A randomized comparative study of albendazole and thiabendazole in chronic strongyloidiasis. [1995.12]
An open randomized study for comparing the efficacy of albendazole and thiabendazole in chronic strongyloidiasis was done in 1990-1992. All 35 patients with positive stool examinations for Strongyloides stercoralis were divided randomly into two groups... Mild changes of transminases observed in 5/23 patients who received albendazole, but none developed clinical hepatitis.
Comparative efficacy of levamisole, thiabendazole and fenbendazole against cattle gastrointestinal nematodes. [1995.05]
Efficacy of two older anthelmintics, levamisole and thiabendazole, was compared with a newer benzimidazole, fenbendazole, against naturally acquired gastrointestinal nematode infections in cattle superimposed with experimental infections of Bunostomum phlebotomum and Dictyocaulus viviparus...
A randomized trial of single- and two-dose ivermectin versus thiabendazole for treatment of strongyloidiasis. [1994.05]
A randomized trial is described comparing ivermectin and thiabendazole for treatment of chronic infection with Strongyloides stercoralis. Subjects received ivermectin (200 micrograms/kg) in a single dose, ivermectin (200 micrograms/kg) on 2 consecutive days, or thiabendazole (50 mg/kg/day) twice daily for 3 consecutive days...
Theophylline and antiparasitic drug interactions. A case report and study of the influence of thiabendazole and mebendazole on theophylline pharmacokinetics in adults. [1990.01]
To determine a change in theophylline pharmacokinetics during concomitant thiabendazole or mebendazole therapy, we studied six normal, healthy male volunteers. Aminophylline was administered intravenously, followed by a 30-h blood sampling period...
Thiabendazole vs. albendazole in treatment of toxocariasis: a clinical trial. [1989.10]
Between 1986 and 1988, 34 patients (age range six to 83 years) with visceral or ocular larva migrans were randomly assigned to a five-day treatment with thiabendazole 2 x 25 mg kg-1 day-1 (15 patients) or albendazole 2 x 5 mg kg-1 day-1 (19 patients)... We recommend albendazole for treatment of visceral and ocular larva migrans with a minimum dose of 10 mg kg-1 daily for five days.
Clinical Trials Related to Mintezol (Thiabendazole)
Study of Patients With Strongyloides Stercoralis Infection [Recruiting]
This study will explore faster and easier ways to detect infection with the intestinal
parasite Strongyloides stercoralis and learn more about the conditions under which it causes
serious disease. Ordinarily, the Strongyloides helminth (type of intestinal worm) causes only
few, if any, symptoms, but in people with weakened immunity it may be very serious, and even
People between 5 and 80 years of age with known or suspected S. stercoralis infection, or
infection with another helminth, such as filariasis, that might cause a cross-reaction with
S. stercoralis may be eligible for this study.
Participants found to be infected with S. stercoralis will be treated with ivermectin,
thiabendazole, or albendazole. In addition, they will undergo the following tests and
- Blood tests and stool samples: Samples will be collected before and after treatment to
check general health status and immune function, and to look for parasites in stool. Up
to 50 milliliters (10 teaspoons) of blood will be drawn in adults and up to 25 ml (5
teaspoons) in children.
- Skin tests: A test similar to those used for tuberculosis and allergies will be
conducted to determine if there is sensitization to products of the parasite. Such a
test might be used as a rapid method to diagnose the infection. About three drops of
several different antigens (proteins) are injected into the skin of the arm. After 15 to
20 minutes, the area is checked to see if a red spot has formed and, if so, the spot is